Biotech Values

[microcapfun]

>>Onxx is now profitable from Nexavar<<

They have lost $68m for the first 9 months of the year. If they hadn't sold Japanese rights to Carfilzomib they would have lost $127m for the first 9 months of the year.

Even non-GAAP they lost money for the first 9 months of the year. (The upfront Japanese licensing fee is obviously one-time and therefore should have not been included in non-GAAP earnings.)


>>The Japanese deal recouped about 40% of the entire Proteolix deal that brought Carfilzomib to Onxx, so I expect some nice cash coming from selling rights to the rest of Asia. I do expect Onxx to partner in Europe. The agreement with Bayer changed on Dec 20 , such that Onxx stated any buyout now will not come at the Nexavar profits.<<

What does any of that have to do with the topic we are discussing??


>>I must say you have been pretty negative towards Onxx for sometime and that hasn't been very accurate.<<

Although I have been long for some time, I am not negative or positive toward Onyx. I am realistic. Try it sometime.

micro